Timothy R. Loveland Associate

Tim counsels investors, lenders, and providers on various healthcare transactional, regulatory, and enforcement matters related to mergers, acquisitions, joint ventures, investments, operations, and corporate governance.

Tim’s practice focuses extensively on healthcare regulatory and enforcement matters and has assisted clients in numerous healthcare-related areas, such as fraud and abuse regulations, health information privacy and security, FDA and life sciences regulatory compliance and risk, and operational and governance integration.  Tim has assisted a broad range of clients on transactional and regulatory matters, including healthcare providers, private equity and other capital investors, banking and financial services, drug and medical device manufacturers and distributors, healthcare technology firms, management services organizations, insurance plans, and healthcare ancillary services firms.  

Tim routinely provides guidance on the following:

  • Federal and state anti-kickback statutes
  • Federal and state referral and fee-splitting prohibitions
  • Federal False Claims Act
  • Corporate practice of medicine
  • Federal Food, Drug, and Cosmetic Act
  • Physician Payments Sunshine Act
  • Prescription Drug Marketing Act
  • HIPAA Privacy and Security Rules and the HITECH Act
  • Federal and state privacy and information security laws
  • State boards of pharmacy and licensure
  • Survey/certification and accreditation
  • Regulatory due diligence for mergers, acquisitions, joint ventures, and divestitures
  • State telemedicine and telepharmacy laws
  • 2018 Farm Bill and state regulation of hemp and hemp-derivative products

Prior to joining the firm, Tim worked as a healthcare consultant and advised hospitals and health systems in the development and operational integration of new hospitals, freestanding EDs, and post-acute venues.  Tim also worked as a law clerk for the American Medical Association updating physician compliance guidelines to ensure consistency with applicable law.


Represented a CBD and hemp extract manufacturer regarding state and federal regulations on their products and assisted them in structuring marketing and sale of products in existing healthcare markets.

Represented a private equity management firm in providing regulatory diligence and structural guidance related to its purchase of a minority interest in a leading, multi-state cannabis platform.

Represented global investment banks on healthcare regulatory and fraud and abuse issues in connection with its lending, acquisition funding, and loan restructuring for health systems, group practices, healthcare IT companies, post-acute venues, and nursing homes.

Counseled healthcare and life sciences companies on formation, restructuring, and syndication of new platforms, joint ventures, and management services organizations.

Represented a global operations management and analytics company in its acquisition of a healthcare utilization review firm and an IT analytics firm.

Conducted internal investigations for health systems, post-acute venues, and physician practices in relation to compliance with privacy and healthcare regulatory policies, procedures, and other applicable regulations.

Provided guidance as outside healthcare regulatory counsel to a national veterinary practice platform.

Conducted internal compliance reviews and audits related to compliance with healthcare laws and regulations and crafted responses to civil and criminal investigations conducted by federal and state government agencies for health systems and pharmaceutical and device clients.

Advised pharmaceutical and medical device manufacturers on FDA matters including state pharmacy/distribution laws, product marketing, product recalls, and manufacturing requirements.

Represented several mobile health application developers as healthcare regulatory counsel in structuring mobile health applications in accordance with healthcare and FDA laws and regulations. 

Represented client as outside healthcare regulatory counsel in a Lanham Act case involving false claims for drug products.

Represented a private equity management firm as healthcare regulatory counsel in connection with its successful acquisition of a leading behavioral health platform.

Provided guidance as outside healthcare regulatory counsel to a national telehealth platform.

  • Loyola University Chicago School of Law, JD, Dean’s List, Certificate in Health Law, Senior Editor, Annals of Health Law Journal, Senior Editor, International Law Review, 2013
  • American University, BA, Government Studies, cum laude, 2008

Young Professionals Board, Lawyers' Committee for Better Housing, 2019

Editor-in-Chief, Health Care Law Monthly, January 2018 – present

Member, American Society for Pharmacy Law

Member, American Health Lawyers Association

Member, Chicago Bar Association

Member, Illinois Association of Healthcare Attorneys

  • Speaker, "Key Developments and Trending Topics on the FDA," Healthcare and Life Sciences Webinar Series, May 20, 2021
  • Moderator, "Regulating Cannabis and CBD Today: State Uncertainty and Federal Restraint," Legal Landscape of Cannabis: Exploring Growth Opportunities Symposium, November 14, 2019
  • Speaker, "Really Green Banking: Cannabis Financial Transaction Considerations," Peer Bank Legal Network, October 23, 2019
  • Moderator, "Improving Revenue Cycle for ASCs," Becker’s 17th Annual Future of Spine & The Spine, Orthopedic and Pain Management-Driven ASC Conference, June 14, 2019
  • Speaker, "Avoiding Regulatory Issues through Effective Due Diligence ," 10th Annual Pharmaceutical and Medical Device Conference, November 15, 2018
  • Moderator, "Key Thoughts on Where and How to Allocate Capital," 9th Annual Becker’s Hospital Review Conference, April 12, 2018
  • Illinois

Selected for inclusion in Best Lawyers: Ones to Watch, Health Care Law, 2021, 2022

Back to top